PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation
- 20 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 56 (5), 1003-1005
- https://doi.org/10.1038/s41409-020-01130-8
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin LymphomaJournal of Clinical Oncology, 2019
- Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic TargetsCurrent Oncology Reports, 2019
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyCancer Discovery, 2019
- Checkpoint inhibitors and acute myelogenous leukemia: promises and challengesExpert Review of Hematology, 2018
- Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantationInternational Journal of Hematology, 2017
- Ipilimumab for Patients with Relapse after Allogeneic TransplantationThe New England Journal of Medicine, 2016
- A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequentBone Marrow Transplantation, 2014
- Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedCancer Treatment Reviews, 2010
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic MalignanciesClinical Cancer Research, 2008